about
Identification and characterization of a novel gene, c1orf109, encoding a CK2 substrate that is involved in cancer cell proliferationRegulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cellsApigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90Molecular determinants of context-dependent progesterone receptor action in breast cancerCRY Drives Cyclic CK2-Mediated BMAL1 Phosphorylation to Control the Mammalian Circadian ClockQuinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1ALow-density crystal packing of human protein kinase CK2 catalytic subunit in complex with resorufin or other ligands: a tool to study the unique hinge-region plasticity of the enzyme without packing biasDifferential phosphorylation of a regulatory subunit of protein kinase CK2 by target of rapamycin complex 1 signaling and the Cdc-like kinase Kns1.Identification of a novel function of CX-4945 as a splicing regulatorTenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in miceA Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian CancerProtein B23/nucleophosmin/numatrin nuclear dynamics in relation to protein kinase CK2 and apoptotic activity in prostate cellsEnhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cellsCK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.Emergence of protein kinase CK2 as a key target in cancer therapyProtein kinases CK1 and CK2 as new targets for neurodegenerative diseases.Protein kinase CK2 localizes to sites of DNA double-strand break regulating the cellular response to DNA damageSynergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.Protein kinase CK2 inhibition induces cell death via early impact on mitochondrial function.Cystic fibrosis transmembrane regulator fragments with the Phe508 deletion exert a dual allosteric control over the master kinase CK2.Drosophila casein kinase 2 (CK2) promotes warts protein to suppress Yorkie protein activity for growth control.Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells.ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells.Protein kinase CK2 in health and disease: CK2: a key player in cancer biologyIdentification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library.Phosphorylation of CRN2 by CK2 regulates F-actin and Arp2/3 interaction and inhibits cell migration.Developmental and growth defects in mice with combined deficiency of CK2 catalytic genes.EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapyTreatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton.Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma.RP1 is a phosphorylation target of CK2 and is involved in cell adhesionIntegrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cellsA Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cellsProtein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development.
P2860
Q21284424-F77F14AB-2B48-42B1-A02A-660CE27E12F6Q24296152-DBD512DC-B152-4EB4-B325-302473E75EE8Q24336102-9260A58F-2447-4281-8EA1-AB86D15DB5ECQ26997928-BA45FDC7-7F98-4310-B33D-BF39415DAA50Q27346393-BABA4482-045B-46A0-A48E-472B616B7948Q27655439-3D5C424F-A3E3-4687-BC91-209EC506B76AQ27670633-D7B0493A-9C70-4161-8959-98C0E14093A8Q27681892-FDDC9E96-239F-44BF-ACD5-DC433C291561Q27935295-541264C0-7BD9-4820-8AE4-5F830737CA57Q28537999-3C453919-3E26-43AB-973D-237B0847A953Q28543800-9C8FF75A-C7D3-4D24-BEA8-24031BCADCD5Q28551341-25333DE5-78DE-40C9-82E0-06841A0C010BQ28574087-B77955BD-1147-46DF-836C-D9071958BED0Q30987315-6072DF05-86CD-4D11-843E-CF1138B2EC74Q33817704-44E7FF60-59D5-453C-A57A-D945762BBBECQ33959504-A9C6CAF2-C5F7-4105-A746-1A148E5FE34EQ34020978-06FFEC20-1D05-4416-BD61-9ACFBA2A9EB0Q34046848-FA0E301C-26FB-40D4-8AA2-060ED040DD69Q34122676-4B40CB37-9F3A-4024-81AA-8D8570AEDE6DQ34190250-27DEFA72-D8E9-4118-B95E-EAF0B85B38B2Q34265716-5645279C-DB7C-4E6C-A5D8-48C78CFA0217Q34353356-A18C8B76-4325-4E07-95AA-9E868B8D71CBQ34521171-D734B0E0-DB44-45CF-9D34-FA9C2F1FF549Q34580407-D457CF8C-1AF9-424D-8532-B2F6A8774445Q34812814-8969D3A2-4F5B-4233-9569-6F7F77BC3C92Q34984681-40152442-BC14-4286-950F-BE8DA77CEA7BQ35096710-DE07BA7B-B3E8-4FC8-82FD-20C7ED17D6DCQ35270830-FF157D54-46C6-4135-8F51-DCE5E40506D5Q35627487-B88A47CC-E3E9-409F-B71E-EFC6662DAB72Q35712790-0E20039B-B2F6-408E-A54A-3032D6B5ACD5Q36095842-FD22C02D-CACD-49BE-B0B8-C12F50DA0C83Q36103054-59B2A754-B9FA-45B4-A8BB-7B041DA25C96Q36185847-0213DEE4-5661-4851-8505-BD9E5E73EA93Q36326939-D39DC985-DD75-430E-8468-4DFDBCA9F066Q36380237-D7958D4E-9520-4157-8DF2-C474B7E35F28Q36544222-9C5741CB-1013-4DD4-AE6D-3A0025B5C6D9Q36981391-041D31E9-6CD0-4596-BE4F-32E0B382FDF9Q37085845-BC0D5FED-FE7F-4511-8D44-745BA9A4479BQ37236792-A6E8D042-45F2-4413-8E42-037AD08FBBA2Q37247661-0FE70EAC-D14A-4F02-A62E-40B8AC13D363
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protein kinase CK2 in human diseases.
@en
Protein kinase CK2 in human diseases.
@nl
type
label
Protein kinase CK2 in human diseases.
@en
Protein kinase CK2 in human diseases.
@nl
prefLabel
Protein kinase CK2 in human diseases.
@en
Protein kinase CK2 in human diseases.
@nl
P1476
Protein kinase CK2 in human diseases
@en
P2093
Olaf-Georg Issinger
P304
P356
10.2174/092986708785132933
P577
2008-01-01T00:00:00Z